98 related articles for article (PubMed ID: 12239111)
1. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate.
Asnicar MA; Köster A; Heiman ML; Tinsley F; Smith DP; Galbreath E; Fox N; Ma YL; Blum WF; Hsiung HM
Endocrinology; 2002 Oct; 143(10):3994-4006. PubMed ID: 12239111
[TBL] [Abstract][Full Text] [Related]
2. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
3. Gene deletion of the PACAP/VIP receptor, VPAC2R, alters glycemic responses during metabolic and psychogenic stress in adult female mice.
Kozlova EV; Bishay AE; Denys ME; Chinthirla BD; Valdez MC; Spurgin KA; Krum JM; Basappa KR; Currás-Collazo MC
J Neuroendocrinol; 2023 Nov; 35(11):e13354. PubMed ID: 37946684
[TBL] [Abstract][Full Text] [Related]
4. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
5. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
6. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.
Lu J; Piper SJ; Zhao P; Miller LJ; Wootten D; Sexton PM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897648
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
9. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice.
Girard BA; Lelievre V; Braas KM; Razinia T; Vizzard MA; Ioffe Y; El Meskini R; Ronnett GV; Waschek JA; May V
J Neurochem; 2006 Oct; 99(2):499-513. PubMed ID: 17029602
[TBL] [Abstract][Full Text] [Related]
10. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
14. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
[TBL] [Abstract][Full Text] [Related]
15. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
16. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
17. Newly-identified receptors for peptide histidine-isoleucine and GHRH-like peptide in zebrafish help to elucidate the mammalian secretin superfamily.
Wu S; Roch GJ; Cervini LA; Rivier JE; Sherwood NM
J Mol Endocrinol; 2008 Nov; 41(5):343-66. PubMed ID: 18757498
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.
Vertongen P; Ciccarelli E; Woussen-Colle MC; De Neef P; Robberecht P; Cauvin A
Endocrinology; 1994 Oct; 135(4):1537-42. PubMed ID: 7925114
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.
Mazzocchi G; Malendowicz LK; Rebuffat P; Gottardo L; Nussdorfer GG
J Clin Endocrinol Metab; 2002 Jun; 87(6):2575-80. PubMed ID: 12050216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]